---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-26-000896"
form_type: "8-K"
ticker: "BBLG"
cik: "0001419554"
company_name: "Bone Biologics Corp"
filed_at: "2026-01-08T23:59:59+00:00"
generated_at: "2026-05-16T11:11:47.174238+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.5
calibrated_materiality_score: 0.5
confidence: "high"
source: SEC EDGAR
---

# Bone Biologics highlights 2025 milestones including $5M offering, 24-month shelf life, Nasdaq compliance

## Summary
- Extended validated shelf life of rhNELL-1 protein product candidate to 24 months (prior 12/18 months).
- Completed $5M registered public offering in Q2 2025 to fund clinical development and IP initiatives.
- Regained Nasdaq minimum bid price compliance in June 2025, maintaining public market access.
- Filed U.S. patent application for recombinant human NELL-1 bone regeneration technology.
- Expects to complete patient enrollment in NB1 first-in-human clinical trial during 2026.

## SEC filing metadata
- accession: 0001493152-26-000896
- form_type: 8-K
- ticker: BBLG
- cik: 0001419554
- company_name: Bone Biologics Corp
- filed_at: 2026-01-08T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.5
- calibrated_materiality_score: 0.5
- confidence: high
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1419554/000149315226000896/0001493152-26-000896-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1419554/000149315226000896/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-26-000896
- JSON: https://secwatch.observer/filing/0001493152-26-000896.json
- Plain text: https://secwatch.observer/filing/0001493152-26-000896.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.